Potential conflict of interest: Nothing to report.
Prognostic significance of von willebrand factor in cirrhosis: A possible mechanism
Article first published online: 29 JUL 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 58, Issue 3, page 1189, September 2013
How to Cite
Eapen, C. E., Elias, J. E., Mackie, I. and Elias, E. (2013), Prognostic significance of von willebrand factor in cirrhosis: A possible mechanism. Hepatology, 58: 1189. doi: 10.1002/hep.26282
- Issue published online: 29 AUG 2013
- Article first published online: 29 JUL 2013
- Accepted manuscript online: 24 JAN 2013 10:02AM EST
- Manuscript Accepted: 6 DEC 2012
- Manuscript Revised: 4 DEC 2012
- Manuscript Received: 19 NOV 2012
To the Editor:
Ferlitsch et al. report on the utility of von Willebrand factor (vWF) in predicting portal hypertension (PH), decompensation, and death in patients with cirrhosis. We wish to comment on a potential mechanism to account for this association.
Physiologically, vWF facilitates platelet adhesion at sites of endothelial damage. vWF is normally secreted by the endothelium as ultralarge vWF (ULvWF) multimers and cleaved into smaller forms by ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13). The presence of ULvWF multimers may reflect reduced ADAMTS13 activity. Decreased ADAMTS13 activity is associated with microvascular occlusion in thrombotic microangiopathies. If operative within the liver, these factors would potentially influence the natural history of liver disease, intensify PH, and thus account for their prognostic significance.
We reported an association of gut disorders with idiopathic noncirrhotic intrahepatic PH (NCIPH), which results from portal venular obliteration. Serum levels of inflammatory cytokines, which are known to stimulate ULvWF multimer release and inhibit ADAMTS13 synthesis,[5, 6] are elevated in patients with celiac disease. Therefore, we studied vWF/ADAMTS13 balance in NCIPH. We found ADAMTS13 deficiency and ULvWF multimers in NCIPH patients in both portal and portopulmonary hypertension and deduced that the above-described mechanisms may be causatively implicated.
The assay used by Ferlitsch et al. would have detected all molecular sizes of vWF, without differentiating between them. It would be interesting to analyze whether ULvWF multimers and ADAMTS13 also have prognostic significance in these patients.
CHUNDAMANNIL E. EAPEN, M.D., D.M.1 JOSHUA E. ELIAS, B.SC., M.B.CH.B.2 IAN MACKIE, B.SC., PH.D., FRCPATH3 ELWYN ELIAS, B.SC., M.D., FRCP4
1Hepatology Department, Christian Medical College, Vellore, India
2Department of Medicine, University Hospitals of Leicester, Leicester, UK
3Hemostasis Research Unit, Department of Hematology, University College London, London, UK
4Liver Unit, University Hospitals of, Birmingham, Birmingham, UK
- 9Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency. J Hepatol 2012 Nov 10. doi:10.1016/j.jhep.2012.11.003., , , , , .